Emily A. Beman

Emily Beman is a counsel in the firm’s Life Sciences Group. She joined Goodwin in 2010.

A selection of Ms. Beman’s recent representative matters is below.

• Advanced Medical Solutions in its acquisition of Sealantis Limited
• bluebird bio in its strategic collaboration with TC BioPharm
• bluebird bio in its strategic collaboration with Regeneron
• BridgeBio Pharma, Inc. subsidiary QED Therapeutics in its $2.45 billion strategic collaboration with Helsinn
• BridgeBio Pharma, Inc. in its joint venture with Maze Therapeutics to advance precision medicine to treat cardiovascular disease.
• BridgeBio Pharma, Inc. subsidiary Eidos Therapeutics in connection with a licensing agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan
• BridgeBio Pharma, Inc. in its launch of its subsidiary, QED Therapeutics, including its in-license of infigratinib from Novartis
• C4 Therapeutics in its strategic collaboration with Roche to develop degrader-based medicines
• C4 Therapeutics in its strategic collaboration with Calico Life Sciences
• Cephalon in its exclusive license agreement with Eagle Pharmaceuticals with a total deal value in excess of $120 million, plus royalties
• CRISPR Therapeutics in its collaboration with Vertex Pharmaceuticals, valued up to $2.6 billion with $105 million upfront
• CRISPR Therapeutics in its collaboration with ViaCyte, focused on stem cell therapies for the treatment of diabetes
• CRISPR Therapeutics in its collaboration with Bayer, valued up to $635 million with $335 million upfront
• CRISPR Therapeutics in its strategic in-licensing and collaboration agreement with Anagenesis Biotechnologies
• Enara Bio in its strategic collaboration and license agreement with Boehringer Ingelheim to discover novel shared antigens for cancer immunotherapies
• Enterome in its collaboration with Takeda
• F-star Alpha in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
• Gadeta in its strategic collaboration with Kite (a Gilead company) to develop novel gamma delta TCR therapies for the treatment of various cancers, by way of an option-to-acquire structure
• Lacerta in its research, collaboration and licensing agreement with UCB Biopharma SRL (“UCB”) pursuant to which the parties will collaborate on developing novel gene therapies focused on a central nervous system disease with a high unmet need
• Naurex in its $560 million sale to Allergan
• Staten Biotechnology in its collaboration with Novo Nordisk to develop novel treatments for dyslipidaemia
• Teva Pharmaceuticals, in its sale of its specialty global women’s health business for a combined value of $2.5 billion, including sale of Paragard®  business to CooperSurgical for $1.1 billion, ex-U.S. women’s health business to CVC Capital Partners for $703 million, and Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
• Teva Pharmaceuticals, in its $40.5 billion acquisition of Allergan’s (fka Actavis/Watson) Global Generic Pharmaceuticals Business
• Teva Pharmaceuticals, in connection with its sale of oncology assets to Ignyta
• Teva Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various brand and generic pharmaceutical patent litigation matters
• Licensing of intellectual property assets from research institutions

Ms. Beman has undertaken a client secondment at bluebird bio.

Prior to joining Goodwin, Ms. Beman was a Special Assistant District Attorney in the Kings County District Attorney’s Office.

While in law school, Ms. Beman was the Alumni Affairs Editor of the Connecticut Law Review.